Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600514 | 0.97 | ROCK2 (0.40) | ROCK2ROCK1CDC42BPBCDC42BPADRD4 | |
| SCHEMBL2600516 | 0.76 | ROCK2 (0.36) | ROCK2ROCK1CDC42BPBCDC42BPA | |
| SCHEMBL2600509 | 0.72 | ROCK2 (0.35) | ROCK2ROCK1CDC42BPBCDC42BPADRD2 | |
| SCHEMBL22548298 | 0.65 | — | — | |
| SCHEMBL28552432 | 0.63 | CHEK1 (0.33) | LRRK2 | |
| SCHEMBL2600506 | 0.63 | AXL (0.50) | ROCK2ROCK1CDC42BPBCDC42BPAAXL | |
| SCHEMBL2600520 | 0.63 | AKT1 (0.38) | ROCK2ROCK1CDC42BPBCDC42BPAAXL | |
| SCHEMBL2600511 | 0.63 | ROCK2 (0.37) | ROCK2ROCK1CDC42BPBCDC42BPAAXL | |
| SCHEMBL18819887 | 0.62 | KDM4E (0.34) | DRD4DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL20758409 | 0.62 | CHEK1 (0.46) | ROCK2ROCK1CDC42BPBCDC42BPAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | PDXK, MAP3K4, PDPK1 | ROCK2 817/4885ROCK1 678/4885CDC42BPB 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.